Cargando…

Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout

BACKGROUND: To assess the efficacy of fenofibrate treatment in combination with urate lowering agents in patients with gout. METHODS: Fourteen male patients with chronic tophaceous or recurrent acute attacks of gout were evaluated in an open-label pilot study of the hypolipidemic agent, fenofibrate...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, You-Hyun, Lee, Chan-Hee, Lee, Jisoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890742/
https://www.ncbi.nlm.nih.gov/pubmed/16913436
http://dx.doi.org/10.3904/kjim.2006.21.2.89
_version_ 1782299311309062144
author Lee, You-Hyun
Lee, Chan-Hee
Lee, Jisoo
author_facet Lee, You-Hyun
Lee, Chan-Hee
Lee, Jisoo
author_sort Lee, You-Hyun
collection PubMed
description BACKGROUND: To assess the efficacy of fenofibrate treatment in combination with urate lowering agents in patients with gout. METHODS: Fourteen male patients with chronic tophaceous or recurrent acute attacks of gout were evaluated in an open-label pilot study of the hypolipidemic agent, fenofibrate (Lipidil Supra® 160 mg/d). Patients were stable on urate lowering agents (allopurinol or benzbromarone) for ≥three months without acute attack for the most recent one month before participating. All patients were being treated with established doses of urate lowering agents without modification throughout the study. Clinical and biochemical assessments including serum uric acid, creatinine, liver function test and fasting serum lipid were measured at (1) baseline (2) after two months of fenofibrate treatment and (3) two months after fenofibrate was withdrawn. RESULTS: Serum uric acid was lowered by 23% after two months of fenofibrate treatment (6.93±2.16 vs. 5.22±1.16 mg/dL; p=0.016). Triglyceride levels were also reduced after fenofibrate treatment (p=0.001). However, this effect was reversed after the withdrawal (p=0.002) of the drug. Alkaline phosphatase was reduced after fenofibrate treatment (p=0.006), but increased 21% after the withdrawal of the drug (p=0.002). By contrast, serum levels of high density lipoprotein and creatinine were increased 9% (p=0.018) and 12% (p=0.006), respectively; however, both levels were significantly decreased to the baseline levels upon withdrawal of fenofibrate. CONCLUSIONS: Fenofibrate can effectively reduce uric acid levels in addition to its known hypolipidemic effect. Fenofibrate may be used as a potential urate lowering agent in patients with gout, especially in those with coexisting hyperlipidemia.
format Online
Article
Text
id pubmed-3890742
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher The Korean Association of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-38907422014-01-15 Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout Lee, You-Hyun Lee, Chan-Hee Lee, Jisoo Korean J Intern Med Original Article BACKGROUND: To assess the efficacy of fenofibrate treatment in combination with urate lowering agents in patients with gout. METHODS: Fourteen male patients with chronic tophaceous or recurrent acute attacks of gout were evaluated in an open-label pilot study of the hypolipidemic agent, fenofibrate (Lipidil Supra® 160 mg/d). Patients were stable on urate lowering agents (allopurinol or benzbromarone) for ≥three months without acute attack for the most recent one month before participating. All patients were being treated with established doses of urate lowering agents without modification throughout the study. Clinical and biochemical assessments including serum uric acid, creatinine, liver function test and fasting serum lipid were measured at (1) baseline (2) after two months of fenofibrate treatment and (3) two months after fenofibrate was withdrawn. RESULTS: Serum uric acid was lowered by 23% after two months of fenofibrate treatment (6.93±2.16 vs. 5.22±1.16 mg/dL; p=0.016). Triglyceride levels were also reduced after fenofibrate treatment (p=0.001). However, this effect was reversed after the withdrawal (p=0.002) of the drug. Alkaline phosphatase was reduced after fenofibrate treatment (p=0.006), but increased 21% after the withdrawal of the drug (p=0.002). By contrast, serum levels of high density lipoprotein and creatinine were increased 9% (p=0.018) and 12% (p=0.006), respectively; however, both levels were significantly decreased to the baseline levels upon withdrawal of fenofibrate. CONCLUSIONS: Fenofibrate can effectively reduce uric acid levels in addition to its known hypolipidemic effect. Fenofibrate may be used as a potential urate lowering agent in patients with gout, especially in those with coexisting hyperlipidemia. The Korean Association of Internal Medicine 2006-06 2006-06-30 /pmc/articles/PMC3890742/ /pubmed/16913436 http://dx.doi.org/10.3904/kjim.2006.21.2.89 Text en Copyright © 2006 The Korean Association of Internal Medicine http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lee, You-Hyun
Lee, Chan-Hee
Lee, Jisoo
Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout
title Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout
title_full Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout
title_fullStr Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout
title_full_unstemmed Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout
title_short Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout
title_sort effect of fenofibrate in combination with urate lowering agents in patients with gout
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890742/
https://www.ncbi.nlm.nih.gov/pubmed/16913436
http://dx.doi.org/10.3904/kjim.2006.21.2.89
work_keys_str_mv AT leeyouhyun effectoffenofibrateincombinationwithurateloweringagentsinpatientswithgout
AT leechanhee effectoffenofibrateincombinationwithurateloweringagentsinpatientswithgout
AT leejisoo effectoffenofibrateincombinationwithurateloweringagentsinpatientswithgout